Defective mismatch repair and benefit from bevacizumab for colon cancer
作者： Katherine Lea Pogue-Geile , Soonmyung Paik
DOI:
关键词: V600E 、 Bevacizumab 、 Adjuvant chemotherapy 、 Tumor tissue 、 Oncology 、 Colorectal cancer 、 Mutation (genetic algorithm) 、 DNA mismatch repair 、 Internal medicine 、 Medicine
摘要: Methods of testing to identify and treat a subset colon cancer patients exhibiting dMMR tumor tissue, who derive significant clinical benefit from the addition bevacizumab standard adjuvant chemotherapy. The presence V600E BRAF mutation is also significance.
lens.org 参考文章(3)
Eric Hedrick, Robert D Mass, Gwendolyn Fyfe, Norman Wolmark, None, Adjuvant cancer therapy ,(2010)
Kimberly D. Siegmund, Daniel J. Weisenberger, Tiffany I. Long, Mihaela Campan, Peter W. Laird, Dna methylation markers associated with the cpg island methylator phenotype (cimp) in human colorectal cancer ,(2006)
Troy M. Bremer, Steven P. Linke, Cornelius A. Diamond, Diagnostic markers predictive of outcomes in colorectal cancer treatment and progression and methods of use thereof ,(2007)